Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Exelixis (EXEL) shares rose 49% this year, but the FDA extended its review of zanzalintinib, a colorectal cancer drug, to 2027. Despite this, the company highlights three growth drivers: Cabometyx's patent protection until 2030, zanzalintinib's potential $4.5B sales by 2033, and a deep pipeline of oncology drugs. Q2 revenue increased 10.6% to $628.7M, with EPS up 26% to $0.82.
How this was made
The 30-second read
Why it matters
Regulatory delay extends the timeline for a potentially high‑revenue drug, likely prompting short‑term sell pressure while long‑term growth remains dependent on pipeline success.
Market read
The news is material for EXEL investors and may influence biotech sector sentiment.
What to watch
Potential for positive data from other indications of zanzalintinib may mitigate the setback.
Background
Exelixis (NASDAQ: EXEL) is a biotech focused on oncology drugs, with Cabometyx as its cash cow and a pipeline including zanzalintinib.
Ticker impact
FDA extended review of Exelixis' zanzalintinib, pushing decision to March 2027, a new regulatory setback for the drug.
likely downside as investors price in delayed approval and revenue postponement
Regulatory delays are material for biotech pipelines; the article is the first report of this extension.
Market effects
Oncology biotech sector may see heightened scrutiny on pending approvals.
US biotech stocks could face short-term pressure.
Limited to investors tracking FDA outcomes; no broad market effect.
Counterpoint
If Exelixus' pipeline depth offsets the delay, the stock could remain resilient.
Key entities
- companyExelixis
US‑listed biotech developing zanzalintinib.
- regulatorFDA
U.S. Food and Drug Administration extending review.
